Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 30%
Buy 15%
Hold 55%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is a biotech company with strong potential for long-term growth, highlighted by their diversified portfolio which is expected to drive an increase in revenue from $1.7B in 2026 to $3-4B in 2030. The recent acquisition of Vega Therapeutics adds the potential blockbuster drug VGA039, which could become the new standard of care for VWD patients, and has a conservative peak sales estimate of $1B+. With a strong pipeline and strategic acquisitions, Incyte is well-positioned for success in the biotech industry, although risks include slower market uptake and delays in securing approvals for late-stage candidates.

Bears say

Incyte is currently overvalued with its DCF-based valuation showing an enterprise value of ~$28B, while the company's current market cap is over $33B. Risks include slower-than-expected market uptake for its drugs, delays in securing approvals for late-stage candidates, and failure to generate favorable data from ongoing programs. The recent deal expansion with Genesis adds significant capital commitment and data integration, while also increasing the target count and potential milestones. Jakafi, the company's leading drug, has shown steady sales growth but may face competition in the future.

Incyte (INCY) has been analyzed by 20 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 15% recommend Buy, 55% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 20 analysts, Incyte (INCY) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.